HealthEquity, Inc. filings document regulatory disclosures for an HSA custodian and consumer-directed benefits administrator. Recent 8-K reports cover operating results and financial condition, guidance furnished under Regulation FD, HSA account and asset metrics, revenue categories, stock repurchase activity, and hedging used to reduce HSA cash repricing risk.
Governance filings record board appointments and committee assignments, annual meeting vote results, auditor ratification, advisory executive compensation votes, executive employment agreement amendments, severance arrangements, equity award terms, and technology-organization leadership responsibility. These disclosures frame the company's capital allocation, compensation governance, risk oversight and public-company reporting obligations.
An insider of the HQY issuer filed a notice of proposed sale under Rule 144 to sell 1,744 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ. The filing lists an aggregate market value for these shares of $166,091.76 and shows that 85,436,286 shares of the same class were outstanding at the time referenced. The shares to be sold were acquired on 03/27/2024 through restricted stock vesting from the issuer as compensation, with the approximate sale date stated as 01/09/2026.
HealthEquity, Inc. EVP & CFO James M. Lucania reported an automatic share withholding transaction involving company common stock. On January 9, 2026, 2,470 shares of HealthEquity common stock were withheld at a weighted average price of $95.236 per share, coded as transaction type "F", which is typically used for satisfying tax or similar obligations using shares. After this transaction, Lucania directly beneficially owned 84,566 shares of HealthEquity common stock.
A holder of HQY common stock has filed a Form 144 notice to sell up to 2,470 shares of common stock on or about 01/09/2026 through Morgan Stanley Smith Barney on the NASDAQ. The filing lists an aggregate market value of 235,233.03 for the planned sale, compared with 85,436,286 shares outstanding of the issuer’s common stock.
The securities to be sold were acquired from the issuer through restricted stock vesting, with 1,871 shares acquired on 09/06/2023 and 599 shares on 03/27/2024, both described as compensation. The signer represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
HealthEquity, Inc. executive Elimelech Rosner reported a small share sale. As EVP and Chief Technology Officer, Rosner sold 2,074 shares of HealthEquity common stock on January 9, 2026 in multiple transactions at a weighted average price of $95.2365 per share. After this transaction, he directly owned 43,668 shares of the company. The price range for the individual trades ran from $95.2358 to $95.2369, and full trade details are available on request from the company or the SEC.
HealthEquity insider Elimelech Rosner has filed a notice of proposed sales of company stock. The filing covers up to 2,074 shares of HealthEquity common stock to be sold through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of 01/09/2026 and an aggregate market value of $197,520.54 at the time of the notice.
The shares to be sold were acquired through restricted stock vesting from the issuer as compensation on 03/30/2022, 03/29/2023, and 03/27/2024. The notice also reports that during the past three months, Rosner sold 10,959 shares of HealthEquity common stock on 12/18/2025, generating gross proceeds of $1,046,090.25.
HealthEquity director and officer Stephen Neeleman reported a disposition of 791 shares of common stock on January 9, 2026, at a weighted average price of $95.2367, leaving 110,744 shares held directly. The filing notes the shares were sold in multiple trades within a narrow price range.
He also reports indirect ownership of common stock held by the Stephen and Christine Neeleman Trust (409,735 shares), his spouse (140,000 shares, with beneficial ownership disclaimed), and Neeleman Family Holdings, LLC (203,000 shares, with beneficial ownership disclaimed except for pecuniary interest. In addition, he holds stock options immediately exercisable for 19,897 shares at $41.28, 14,228 shares at $61.72, and 15,337 shares at $73.61.
A shareholder of HQY has filed a Rule 144 notice to sell 791 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ exchange. The filing lists an aggregate market value of 75,332.26 for these shares and states that 85,436,286 shares of the issuer’s common stock are outstanding.
The shares to be sold were acquired as compensation through restricted stock vesting from the issuer on 03/30/2022 (245 shares), 03/29/2023 (330 shares), and 03/27/2024 (216 shares). The approximate date of sale indicated in the notice is 01/09/2026. The signer represents that they do not know of any material adverse, non‑public information about the issuer’s operations.
HealthEquity, Inc. executive Delano Ladd, EVP and General Counsel, reported a small sale of company stock. On January 9, 2026, he disposed of 739 shares of common stock at a weighted average price of $95.237 per share, through multiple trades between $95.2363 and $95.2379. After this transaction, he beneficially owned 73,240 shares of HealthEquity common stock in direct ownership.
HealthEquity, Inc. insider Delano Ladd has filed a notice of proposed sale of 739 shares of common stock through Morgan Stanley Smith Barney on or about 01/09/2026, with the shares listed on NASDAQ. The filing reports an aggregate market value of $70,380.17 for this planned sale, compared with 85,436,286 shares of the issuer’s common stock outstanding.
The shares to be sold were acquired through restricted stock vesting from the issuer on 03/30/2022, 03/29/2023, and 03/27/2024, and are described as compensation. The notice also lists sales over the past three months, including 1,500 shares sold on each of 10/20/2025, 11/20/2025, and 12/19/2025, with gross proceeds of $138,105.00, $156,840.00, and $142,080.00, respectively.
HealthEquity, Inc. filed a current report to let investors know it has issued a press release with its initial outlook for the fiscal year ending January 31, 2027 and reaffirmed its previously provided guidance for the fiscal year ending January 31, 2026. The outlook and guidance details are contained in the press release attached as Exhibit 99.1.
The company plans to discuss these estimates during a presentation at the 44rd Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 3:00 PM Pacific Time. An audio webcast of the presentation and the related conference materials will be available through the investor section of its website at ir.healthequity.com. The press release is being furnished to regulators, not filed, which means it is not automatically incorporated into other securities law filings.